| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hopital d'Instruction des Armees Val-de-Grace; Stephane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; A. Thiery Vuillemin, Jean Minjoz Hospital, Besancon; Nadine Houede, Institut de Cancerologie du Gard-Centre Hospitalier Universitaire Caremeau, Nimes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis fur Urologie; Kurt Miller, Charite-Universitatsmedizin Berlin, Berlin; Martin Bogemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nurtingen; Arnulf Stenzl, University Hospital, Tubingen, Germany; Fred Saad, Centre Hospitalier de I'Universite de Montreal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia. smith.matthew@mgh.harvard.edu. Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hopital d'Instruction des Armees Val-de-Grace; Stephane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; A. Thiery Vuillemin, Jean Minjoz Hospital, Besancon; Nadine Houede, Institut de Cancerologie du Gard-Centre Hospitalier Universitaire Caremeau, Nimes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis fur Urologie; Kurt Miller, Charite-Universitatsmedizin Berlin, Berlin; Martin Bogemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nurtingen; Arnulf Stenzl, University Hospital, Tubingen, Germany; Fred Saad, Centre Hospitalier de I'Universite de Montreal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia. alt-title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology accession-num: 27400947 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 |
Institut de Recherche en Cancérologie de
